Hemostemix Inc.
HEM
Clasificación en acciones
#32551
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Precio por acción
$0.04268108
Última sincronización: 2026-10-21
Capitalización bursátil
$9.02M
Cambio (1 día)
5.73%
Cambio (1 año)
-42.09%
País
CA
Comercio Hemostemix Inc. (HEM)
Categoría
Healthcare
Historial del precio de la acción de Hemostemix Inc. (HEM)
Precio más alto de cierre: $0.04 el 2026-10-01
Precio más bajo de cierre: $0.00 el 2005-11-01
Precio más bajo de cierre: $0.00 el 2005-11-01
Historial del precio de la acción de Hemostemix Inc. desde 2005 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $535.33 | 25.53% |
US
|
|
| $196.80 | 632.94% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.65 | 7.67% |
NL
|
